FINNENCE ▪ THE WIRE FILE
THE WIRE · № 57118
News■ Unclear/unknown
CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-09-30 11:00 UTC
LAST UPDATE2026-09-30 11:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Conference data presentations for a blood-purification device are incremental, not pivotal.
Incremental device data, no commercial catalyst
CATALYST TO WATCH
Peer-reviewed results or regulatory decisions
MAIN RISK
Presentations may not translate to sales
FULL DISPATCH
PRINCETON, N.J., Sept. 30, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces upcoming data presentations using CytoSorb® in open heart...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
EASD 2026 | Ecnoglutide Demonstrates Favorable Safety Profile in Adolescents with Obesity2026-09-30 11:00 UTC
EASD 2026 | Ecnoglutide Demonstrates Favorable Safety Profile in Adolescents with Obesity2026-09-30 11:00 UTC
←CORRELATIONshares Healthcare
Wake County leaders tout growth, defend WakeMed-Atrium merger2026-09-29 23:13 UTC
Wake County leaders tout growth, defend WakeMed-Atrium merger2026-09-29 23:13 UTC
←CORRELATIONshares Healthcare
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 20262026-09-30 05:30 UTC
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 20262026-09-30 05:30 UTC
←CORRELATIONshares Healthcare
Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist2026-09-30 05:57 UTC
Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist2026-09-30 05:57 UTC
←CORRELATIONshares Healthcare
Leads To Development Joins Clarenta Group, Strengthening Early-Stage Drug Development Expertise2026-09-30 08:00 UTC
Leads To Development Joins Clarenta Group, Strengthening Early-Stage Drug Development Expertise2026-09-30 08:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.